Ver publicación 

Mostrar el registro sencillo de la publicación

New drug design avenues targeting alzheimer’s disease by pharmacoinformatics-aided tools

dc.contributor.authorArrué, Lily
dc.contributor.authorCigna-Méndez, Alexandra
dc.contributor.authorBarbosa, Tábata
dc.contributor.authorBorrego-Muñoz, Paola
dc.contributor.authorStruve-Villalobos, Silvia
dc.contributor.authorOviedo, Victoria
dc.contributor.authorMartínez-García, Claudia
dc.contributor.authorSepúlveda-Lara, Alexis
dc.contributor.authorMillán, Natalia
dc.contributor.authorMárquez Montesinos, José C. E
dc.contributor.authorMuñoz, Juana
dc.contributor.authorSantana, Paula A
dc.contributor.authorPeña-Varas, Carlos
dc.contributor.authorBarreto, George E
dc.contributor.authorGonzález, Janneth
dc.contributor.authorRamírez, David
dc.contributor.authorArrué
dc.date.accessioned2022-10-24T13:35:16Z
dc.date.available2022-10-24T13:35:16Z
dc.date.issued2022
dc.identifier.urihttp://repositorio.ucm.cl/handle/ucm/4120
dc.description.abstractNeurodegenerative diseases (NDD) have been of great interest to scientists for a long time due to their multifactorial character. Among these pathologies, Alzheimer’s disease (AD) is of special relevance, and despite the existence of approved drugs for its treatment, there is still no efficient pharmacological therapy to stop, slow, or repair neurodegeneration. Existing drugs have certain disadvantages, such as lack of efficacy and side effects. Therefore, there is a real need to discover new drugs that can deal with this problem. However, as AD is multifactorial in nature with so many physiological pathways involved, the most effective approach to modulate more than one of them in a relevant manner and without undesirable consequences is through polypharmacology. In this field, there has been significant progress in recent years in terms of pharmacoinformatics tools that allow the discovery of bioactive molecules with polypharmacological profiles without the need to spend a long time and excessive resources on complex experimental designs, making the drug design and development pipeline more efficient. In this review, we present from different perspectives how pharmacoinformatics tools can be useful when drug design programs are designed to tackle complex diseases such as AD, highlighting essential concepts, showing the relevance of artificial intelligence and new trends, as well as different databases and software with their main results, emphasizing the importance of coupling wet and dry approaches in drug design and development processes.es_CL
dc.language.isoenes_CL
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
dc.sourcePharmaceutics, 14(9), 1914es_CL
dc.subjectAlzheimer’s diseasees_CL
dc.subjectDrug designes_CL
dc.subjectComputational polypharmacologyes_CL
dc.subjectBioinformaticses_CL
dc.subjectPharmacoinformaticses_CL
dc.subjectMultitarget directed ligandses_CL
dc.subjectProtein–protein interaction networkes_CL
dc.subjectPharmacophorees_CL
dc.titleNew drug design avenues targeting alzheimer’s disease by pharmacoinformatics-aided toolses_CL
dc.typeArticlees_CL
dc.ucm.indexacionScopuses_CL
dc.ucm.indexacionIsies_CL
dc.ucm.doidoi.org/10.3390/pharmaceutics14091914es_CL


Ficheros en la publicación

Vista Previa No Disponible
Nombre:
license_rdf
Tamaño:
811bytes
Formato:
application/rdf+xml
Ver/
Thumbnail
Nombre:
arrue_l_new.pdf
Tamaño:
5.035Mb
Formato:
PDF
Ver/

Esta publicación aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo de la publicación

Atribución-NoComercial-SinDerivadas 3.0 Chile
Excepto si se señala otra cosa, la licencia de la publicación se describe como Atribución-NoComercial-SinDerivadas 3.0 Chile